ČESKÁ UROLOGIE / CZECH UROLOGY – 3 / 2020

182 PŘEHLEDOVÝ ČLÁNEK Ces Urol 2020; 24(3): 173–182 24. Buyse G, Waldeck K, Verpoorten C, et al. Intravesical oxybutynin for neurogenic bladder dysfunction: less systemic side effects due to reduced first pass metabolism. J Urol 1998; 160(3 Pt 1): 892–896. 25. Cheng T, Shuang W‑b, Jia D‑d, et al. Efficacy and safety of onabotulinumtoxin A in patients with neurogenic detrusor overactivity: A systematic review and meta‑analysis of randomized controlled trials. PLOS ONE 2016; 11(7): e0159307. 26. De Ridder D, Van Poppel H, Baert L, et al. From time dependent intermittent selfcatheterisation to volume dependent selfcatheterisation in Multiple Sclerosis using the PCI 5000 Bladdermanager(R). Spinal cord 1997; 35: 613–616. 27. Giannantoni A, Scivoletto G, Di Stasi SM, et al. Urological dysfunctions and upper urinary tract invol‑ vement in multiple sclerosis patients. Neurourol Urodyn 1998; 17(2): 89–98. 28. Wall BM, Dmochowski RR, Malecha M, et al. Inducible nitric oxide synthase in the bladder of spinal cord injured patients with a chronic indwelling urinary catheter. J Urol 2001; 165(5): 1457–1461. 29. Ozawa H, Uematsu K, Ohmori H, et al. Long‑term usefulness and safety of the contemporary balloon catheter. Nihon Hinyokika Gakkai Zasshi. 2005; 96(5): 541–547. 30. Chartier‑Kastler EJ, Ruud Bosch JL, Perrigot M, et al. Long‑term results of sacral nerve stimulation (S3) for the treatment of neurogenic refractory urge incontinence related to detrusor hyperreflexia. J Urol 2000; 164(5): 1476–1480. 31. Zachoval R, Pitha J, Medova E, et al. Augmentation cystoplasty in patients with multiple sclerosis. Urol Int 2003; 70(1): 21–26. 32. Phé V, PakzadM, Curtis C, et al. Urinary tract infections inmultiple sclerosis. Mult Scler 2016; 22(7): 855–861. 33. Marrie RA, Elliott L, Marriott J, et al. Dramatically changing rates and reasons for hospitalization in multiple sclerosis. Neurology 2014; 83(10): 929–937. 34. Mahadeva A, Tanasescu R, Gran B. Urinary tract infections in multiple sclerosis: under‑diagnosed and under‑treated? A clinical audit at a large University Hospital. Am J Clin Exp Immunol 2014; 3(1): 57–67. 35. Sibley WA, Bamford CR, Clark K. Clinical viral infections and multiple sclerosis. Lancet 1985; 1(8441): 1313–1315. 36. Winkelmann A, Loebermann M, Reisinger EC, et al. Multiple sclerosis treatment and infectious issues: update 2013. Clin Exp Immunol 2014; 175(3): 425–438. 37. Guo ZN, He SY, Zhang HL, et al. Multiple sclerosis and sexual dysfunction. Asian J Androl 2012; 14(4):530–535. 38. Shridharani AN, Brant WO. The treatment of erectile dysfunction in patients with neurogenic disease. Transl Androl Urol 2016; 5(1): 88–101. 39. Foley FW, LaRocca NG, Sanders AS, Zemon V. Rehabilitation of intimacy and sexual dysfunction in couples with multiple sclerosis. Mult Scler 2001; 7(6): 417–421. 40. Fragala E, Russo GI, Di Rosa A, et al. Relationship between urodynamic findings and sexual function in multiple sclerosis patients with lower urinary tract dysfunction. Eur J Neurol 2015; 22(3): 485–492. 41. Lombardi G, Musco S, Wyndaele JJ, et al. Treatments for erectile dysfunction in spinal cord patients: alternatives to phosphodiesterase type 5 inhibitors? A review study. Spinal Cord 2015; 53(12): 849–854. 42. Cardenas DD, Ditunno JF, Graziani V, et al. Two phase 3, multicenter, randomized, placebo‑controlled clinical trials of fampridine‑SR for treatment of spasticity in chronic spinal cord injury. Spinal Cord 2014; 52(1): 70–76. 43. Kessler TM, Fowler CJ, Panicker JN. Sexual dysfunction in multiple sclerosis. Expert Rev Neurother 2009; 9(3): 341–350.